Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 01
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
BioNTech SE
BNTX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$98.30
-0.27
-0.27%
Últ. Act.: Sep 30, 4:23 PM
$98.00
-0.57
-0.58%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
BioNTech Financials
BioNTech (BNTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est
BioNTech (NASDAQ:BNTX) lowers FY2026 sales outlook from $2.328 billion-$2.678 billion to $1.860 billion-$2.209 billion vs $2.500 billion estimate.
Benzinga Newsdesk
PRO
BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.58) per share which missed the analyst consensus estimate of $(2.34) by 10.26 percent. This is a 41.76 percent decrease over losses of $(1.82) per share from the
Benzinga Newsdesk
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
BioNTech shares fall after Q1 revenue miss and wider net loss, despite lower-than-expected loss and long-term cost-saving plans.
Vandana Singh
Earnings Scheduled For May 5, 2026
Benzinga Insights
PRO
BioNTech Affirms FY2026 Sales Guidance of $2.328B-$2.678B vs $2.560B Est
BioNTech (NASDAQ:BNTX) affirms FY2026 sales outlook from $2.328 billion-$2.678 billion to $2.328 billion-$2.678 billion vs $2.560 billion estimate.
Benzinga Newsdesk
PRO
BioNTech Q1 Adj. EPS $(2.28) Beats $(2.52) Estimate, Sales $138.000M Miss $214.620M Estimate
BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.28) per share which beat the analyst consensus estimate of $(2.52) by 9.52 percent. This is a 25.27 percent decrease over losses of $(1.82) per share from the same
Benzinga Newsdesk
